Latest news with #Kymriah
Yahoo
09-07-2025
- Business
- Yahoo
$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information
ARLINGTON, Va., July 9, 2025 /PRNewswire/ -- Kalorama Information, a leading authority in healthcare market research, announces the release of its new report, Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024–2030). The study reveals that the global market for cell and gene therapy (CGT) is poised to surge from $14.1 billion in 2024 to more than double by 2030, driven by scientific advancements, regional market expansion, and next-generation product approvals. "Novartis is currently leading the cell and gene therapy market with sales generated from its oncology CAR-T therapy Kymriah, its acquired gene therapy for muscular atrophy Zolgensma, and Leqvio. Gilead Sciences, with Yescarta and Tecartus, is the second largest provider of cell and gene therapy, specializing in oncology CAR-T therapy," said Justin Saeks, Senior Analyst at Kalorama and the report's author. As oncology and rare genetic diseases continue to dominate the CGT landscape, new growth is emerging in therapeutic areas like musculoskeletal, dermatology, and cardiovascular applications. While oncology drives revenue in North America, neurology leads in Europe, underscoring distinct regional dynamics. The report offers detailed market estimates, regional forecasts, and competitive insights, and highlights: 15%+ CAGR in oncology led by CAR T-cell therapies and lymphoma treatments 17% market share held by Novartis, followed by Kite/Gilead at 14% Key shifts in RNA/antisense therapy adoption, with regulatory ambiguity on mRNA's classification across regions The CGT industry now faces its next major inflection point: the industrialization and standardization of manufacturing processes, where automation and closed systems are becoming imperative. Business leaders are also innovating new models to address cost, access, and scalability. Why This Matters With over 100+ tables and charts, this report provides strategic guidance for: R&D and pipeline teams evaluating target diseases and emerging competitors Corporate development leaders exploring M&A and early-stage investment targets Marketers and regulatory professionals planning product launches and global expansion The report is essential reading for executives in biopharma, biotech startups, CDMOs, life sciences investment, and healthcare strategy. Download the Report Purchase or learn more about the report here:Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030) Also available:Companion Report – Cell and Gene Therapy Market Deals: Investment, M&A, and Partnerships, 2021–2025 (3rd Edition) Media Contact Alisa AlvichMarketing Sales & Research Inquiries Sheri DavieSales Director, Science and Medicine View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
28-06-2025
- Health
- Time of India
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
Bengaluru: The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a safety program to protect patients from risky drugs, for currently approved CAR-T cell immunotherapies. REMS is required by the FDA to ensure a drug's benefits outweigh its risks by managing serious safety concerns. The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed warnings for cytokine release syndrome and neurological toxicities, and medication guides. The cancer therapies include Bristol-Myers Squibb's Breyanzi and its partnered therapy Abecma with 2seventy bio , Johnson & Johnson's unit Janssen and Legend Biotech's Carvykti, Novartis AG's Kymriah, and Gilead Sciences' unit Kite's Tecartus and Yescarta. Bristol-Myers Squibb and Gilead Sciences did not immediately respond to Reuters' requests for comment. These are gene therapies that are currently approved to treat blood cancers, such as multiple myeloma and certain types of leukemia and lymphoma, the health regulator said. CAR-T treatment generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body. In January 2024, the FDA asked several drugmakers to add a serious warning on the label of their cancer therapies that use CAR-T technology after reports of T-cell malignancies and adverse events identified since approval. The FDA earlier said the risk of T-cell malignancies including leukemia and lymphoma applies to all therapies in the class and can lead to hospitalization and death.
Yahoo
26-03-2025
- Business
- Yahoo
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
CHICAGO, March 26, 2025 /PRNewswire/ -- The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%. The surge in demand is fueled by the success of FDA-approved CAR T-cell products such as Yescarta and Kymriah, which have demonstrated strong market performance. In 2023, Yescarta generated USD 1.4 billion in sales, with over 1,300 patients treated, while Kymriah achieved USD 443 million in sales in 2024, driven by its effectiveness in paediatric acute lymphoblastic leukemia (pALL) and follicular lymphoma (FL) outside the United States. More recently, Carvykti recorded net sales of USD 500 million within its first year of launch, underscoring the increasing demand for CAR T-cell therapies. Download Sample Copy: The therapy plays a critical role in treating relapsed and refractory hematologic cancers. In the U.S., hematologic cancers such as leukemia, lymphoma, and myeloma are diagnosed approximately every three minutes, highlighting an urgent need for innovative treatments. With government support and favorable reimbursement policies, the eligibility of hematologic cancer patients for CAR T-cell therapy increased from 2.7% in 2017 to 3.9% in 2023. Additionally, ongoing research focuses on expanding target antigens beyond CD19 and BCMA to improve treatment efficacy and broaden applications. Despite its potential, high costs and complex manufacturing processes pose significant barriers to broader adoption. The list price for CAR T-cell therapies ranges from USD 373,000 to USD 475,000 per infusion, with total treatment costs exceeding USD 500,000 per patient after factoring in hospitalization and follow-up care. Even with reimbursement programs and patient assistance services, financial burdens persist. Moreover, manufacturing remains a major challenge, requiring specialized equipment, stringent quality control, and substantial investment. Production costs alone can exceed USD 100,000 per patient, and the limited number of certified therapy centers—only 311 in the U.S. as of July 2024—further restricts accessibility. However, industry stakeholders are actively addressing these challenges. Efforts to streamline production, optimize cost efficiency, and expand therapy centers are underway. Additionally, manufacturers offer patient assistance programs, such as Kite Konnect by Gilead, which help with reimbursement support, logistics, and treatment navigation. With continuous research, technological advancements, and increased investment, CAR T-cell therapy is poised for broader adoption, offering new hope to patients battling aggressive blood cancers while also paving the way for future applications in additional therapeutic areas. Market Forecast (2033) USD 27.5 Billion CAGR 26.2 % Top Drivers Rising incidence of haematological cancer Increasing R&D investment & rising healthcare expenditure Expanding applications in oncology and autoimmune diseases Top Opportunities Growing research on solid tumours Increasing focus on developing personalized medicine Recent advances in gene editing and allogeneic therapies Top Challenges High development costs and manufacturing complexities Technological Milestone: Next-Level Innovation Driving CAR T-Cell Therapy's Expansion Breakthroughs in genome editing and cell engineering are driving CAR T-cell therapies to achieve enhanced efficacy and safety. Techniques such as CRISPR-Cas9, TALENs, and Zinc Finger Nucleases (ZFNs) optimize T-cell function, prevent antigen escape, and improve persistence in the body. By facilitating targeted genetic modifications, these tools strengthen the therapeutic potential of CAR T-cell therapies beyond oncology. While single-target CAR T-cell therapies have improved survival rates in hematologic malignancies, relapse remains a challenge due to antigen escape. To address this, dual-targeting CAR T-cell therapies have emerged, designed to recognize multiple cancer markers and mitigate treatment resistance. Clinical studies confirm that these approaches enhance efficacy and safety, though ongoing research is refining bispecific CAR structures and optimizing T-cell transduction efficiency. Researchers are also expanding CAR T-cell applications to autoimmune diseases, where they aim to selectively eliminate overactive B-cells and achieve long-term, drug-free remission in conditions such as lupus and rheumatoid arthritis. The CAR T-cell therapy market is currently dominated by autologous treatments, accounting for over 90% of therapies. This personalized approach — involving the extraction, modification, and reinfusion of a patient's own T-cells — has demonstrated strong clinical outcomes with established treatments like Yescarta and Kymriah. However, allogeneic CAR T-cell therapies are rapidly advancing as a scalable, off-the-shelf alternative. By utilizing healthy donor T-cells, allogeneic therapies offer faster production timelines and broader accessibility. Researchers are leveraging gene-editing tools such as CRISPR-Cas9 to mitigate risks like graft-versus-host disease (GvHD) and immune rejection, enhancing the safety and efficacy profile of these treatments. While CAR T-cell therapy remains a leading monotherapy in hematologic malignancies, combination approaches are gaining traction. Combining CAR T-cell therapy with checkpoint inhibitors — such as PD-1/PD-L1 blockers — is emerging as a powerful strategy to enhance T-cell persistence and reduce immune evasion. These combinations are expanding therapeutic possibilities in both oncology and immune-related conditions. As genome editing technologies advance and dual-targeting strategies continue to evolve, CAR T-cell therapy is poised to achieve transformative growth. The convergence of improved engineering techniques, expanded clinical applications, and combination strategies is driving CAR T-cell therapy's expansion into broader treatment landscapes beyond oncology, paving the way for next-generation healthcare solutions. Global CAR T-Cell Therapy Boom: Regional Forces Driving the Future of Immuno-Oncology The global CAR T-cell therapy market is expanding rapidly, driven by advancements in cancer immunotherapy, growing clinical research, and evolving reimbursement policies. Regional dynamics are crucial in shaping this growth, with North America, Europe, and Asia-Pacific playing key roles in driving innovation, access, and commercialization. North America leads the market, driven by early approvals, robust biotech infrastructure, and favorable reimbursement policies. The United States dominates the region, benefiting from Medicare's MS-DRG 018 program, which offers a base reimbursement of $247,939 for inpatient CAR T-cell treatments. Established CPT codes, such as 0537T (for T-cell harvesting) and 0540T (for CAR T-cell administration), further streamline cost management. In Canada, CAR T-cell therapies, often priced at ~$500,000, are covered under Ontario Health funding in eligible cases, though reimbursement remains limited to select provinces. To address these gaps, Canadian authorities are investing in developing domestic CAR T-cell therapies. Europe is following closely behind, with Germany and France leading due to supportive regulatory frameworks and improving reimbursement systems that expand access to CAR T-cell treatments. Ongoing efforts to enhance healthcare policies are further improving patient access. The Asia-Pacific region is witnessing rapid growth, driven by rising investments, accelerating clinical research, and evolving regulations. China and Japan are at the forefront, with domestic biotech firms actively advancing CAR T-cell innovations. In India, CAR T-cell adoption faced early challenges due to infrastructure and insurance limitations. However, in October 2023, the CDSCO approved NexCAR 19 (Actalycabtagene autoleucel), India's first CAR T-cell therapy, developed by ImmunoACT in collaboration with Tata Memorial Centre. Priced at ₹30-40 lakhs (~$34,000 - 45,000), NexCAR 19 is significantly more affordable than global alternatives, marking a breakthrough for resource-limited settings. The Middle East & Africa region holds a smaller market share, constrained by limited healthcare infrastructure. However, GCC nations like Saudi Arabia and the UAE are increasingly investing in CAR T-cell therapy expansion. As reimbursement frameworks advance and global collaborations grow, CAR T-cell therapy is evolving from a high-cost niche treatment to a mainstream cancer immunotherapy, poised to transform the future of oncology care worldwide. Recent Advancements and Key Players in the Car T Cell Therapy Market Several prominent players are driving innovation in the CAR T-cell therapy market, including Novartis AG, Bluebird Bio, Inc., Cellectis, Bristol-Myers Squibb, Merck & Co., Inc., Juno Therapeutics, Inc., Celyad Oncology, Celgene Corporation, Sorrento Therapeutics, Inc., Miltenyi Biotech, Intellia Therapeutics, Pfizer, Inc., Autolus Therapeutics, Gilead Sciences, Inc. (Kite Pharma Inc.), Cartesian Therapeutics, Inc., and Caribou Biosciences, Inc. These companies are at the forefront of advancing CAR T-cell therapies, focusing on enhancing treatment efficacy, improving manufacturing processes, and expanding patient accessibility in the field of immuno-oncology. For instance, in February 2025, bluebird bio entered a definitive agreement for acquisition by Carlyle and SK Capital. Under this agreement, bluebird's stockholders will receive USD 3.00 per share in cash, along with a contingent value right (CVR) of USD 6.84 per share in cash, payable upon achieving a specified net sales milestone. Upon closing, David Meek (former CEO of Mirati Therapeutics and Ipsen) is expected to assume the role of bluebird's CEO, strengthening the company's leadership in cell therapy development. Similarly, in February 2024, AstraZeneca completed its acquisition of Gracell Biotechnologies, bolstering its cell therapy pipeline with GC012F, a FasTCAR-enabled BCMA and CD19 dual-targeting autologous CAR T-cell therapy. The upfront cash component valued the transaction at approximately USD 1.0 billion, with the potential to reach USD 1.2 billion through milestone-based contingent payments. Further, Vyriad, Inc. and Novartis announced a strategic collaboration in November 2024 to develop in vivo CAR T-cell therapies. This partnership combines Vyriad's targeted lentiviral vector platform with Novartis' cell therapy expertise to identify and advance innovative CAR T-cell candidates. Under the agreement, Vyriad will receive an upfront payment, along with milestone-based payments and tiered royalties for successful programs. These advancements underscore the rapid progress in CAR T-cell therapy development, improving treatment accessibility and expanding the therapeutic landscape. With ongoing investments, acquisitions, and strategic collaborations, the CAR T-cell therapy market is poised for continued growth and innovation. Future Outlook: Transforming the CAR T-Cell Therapy Market The CAR T-cell therapy market is set for substantial expansion, driven by continuous advancements in cell engineering, personalized immunotherapies, and biomanufacturing innovations. With increasing clinical success and expanding treatment indications, the market presents significant opportunities for biotechnology companies, healthcare providers, and investors to revolutionize cancer care. Industry experts predict a surge in the development of next-generation CAR T therapies, focusing on improved efficacy, reduced toxicity, and broader applications beyond hematologic malignancies. Notable advancements include the exploration of CAR T therapies targeting solid tumors, along with the rise of allogeneic "off-the-shelf" therapies designed to enhance scalability and accessibility. Companies like Novartis AG, Gilead Sciences (Kite Pharma), and Bristol-Myers Squibb are at the forefront, driving innovative research aimed at treating aggressive cancers, autoimmune diseases, and even select viral infections. Technological advancements, such as the integration of artificial intelligence (AI) in cell design, automation in manufacturing, and in vivo CAR T delivery platforms, are expected to streamline production, improve consistency, and reduce costs. Additionally, regulatory agencies are increasingly adopting accelerated approval pathways, promoting faster commercialization of novel therapies. By 2030, CAR T-cell therapies are expected to become more widely integrated into oncology care, transforming treatment paradigms for both hem and solid tumors. Achieving this vision will depend heavily on overcoming current challenges like manufacturing bottlenecks, therapy response rates, and side effect management. Enhanced reimbursement frameworks, cost-sharing models, and patient support programs will also play a pivotal role in improving affordability and ensuring broader patient access. As the industry continues to evolve, CAR T-cell therapy is positioned to transition from a specialized treatment option to a widely accessible immuno-oncology breakthrough, redefining cancer care on a global scale. Inquiry Before Buyinghttps:// Key Players in CAR T Cell Therapy Market Novartis AG Bluebird Bio, Inc. Cellectis Bristol-Myers Squibb Merck & Co., Inc. Juno Therapeutics, Inc. Celyad Oncology Celgene Corporation Sorrento Therapeutics, Inc. Miltenyi Biotech Intellia Therapeutics Pfizer, Inc. Autolus Therapeutics Gilead Sciences, Inc. (Kite Pharma Inc.) Cartesian Therapeutics, Inc. Caribou Biosciences, Inc. Other Prominent Players Segments Covered in The Report By Indication Leukemia Lymphoma Myeloma By Source Autologous Allogenic By Type of Therapy Monotherapy Combination Therapy By Product ABECMA Breyanzi Carvykti Kymriah Tecartus Yescarta Others By Administration Setting Inpatient Outpatient By Region North America Europe Asia-Pacific Middle East & Africa South America Get Free Customization on this Report: Explore More Reports: Cancer Gene Therapy Market: By Therapy (Gene-Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer); End Users (Biopharmaceutical Companies, Hospitals & Research Institutes, Diagnostic centers, Others); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 Hemophilia Treatment Market: By Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others); Product (Recombinant coagulation factor concentrates , Plasma-derived coagulation factor concentrates, Desmopressin, Antifibrinolytic agents, Gene therapy products, and Others); Patients (Pediatric (0 to 4 yrs, 5 to 13 yrs, and 14 to18 yrs) and Adult (19 to 44 yrs and 45+ yrs); Form (Powders, Liquids & Gels, Tablets & Capsules, and Others)); Treatment Type (On-Demand Treatment, Prophylactic Treatment, and Immune Tolerance Induction (ITI) Therapy); Route of Administration (Intravenous and Subcutaneous); End User (Hospitals, Specialty Clinics, Home Care Settings, and Hemophilia Treatment Centers (HTCs)) and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 Herbal Medicine Market: By Product (Ginseng, Ashwagandha, Flaxseed, Ginko, Cinnamon, Cranberry, Horsetail, Horehound, Yohimbe, Black Cohosh, Senna, Echinacea, Valerian, Saw Palmetto, Aloe Vera, Bioflavonoid complex, Milk Thistle, Ginger, Garlic, Horny Goat Weed, Red Yeast Rice, Bromelain, and Others); Type (Western Herbalism, Ayurveda, Traditional Chinese Medicine, and Others); Sources (Leaves, Roots, Flowers, Stem, Seeds, Bark, and Others); Form (Powders, Liquids & Gels, Tablets & Capsules, and Others); Form (Powders, Liquids & Gels, Tablets & Capsules, and Others); Application(Pharmaceutical & Nutraceutical (Inflammation & Pain, Digestive Health, Respiratory Health, Skin Conditions, Stress and Anxiety, Immune Support, Cardiovascular health, Cognitive Function, Hormonal Imbalance, and Others), Food & Beverages (Herbal teas and beverages and Functional foods), and Personal Care & Beauty Products (Anti-aging products and Hair and scalp care)); and Distribution Channel (Online (Online Brand Stores, e-market places) and Offline (Hospitals, Retail Pharmacies, and Others)) ; Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 Stem Cell Therapy Market: By Cell Source (Adipose tissue-derived MSCs (mesenchymal stem cells), Bone marrow-derived MSCs, Placental and umbilical cord-derived MSCs, Other Cell Sources); Type (Autologous stem cell therapy and Allogeneic Stem Cell Therapy); Delivery Method (In Vivo and Ex Vivo); Therapeutic Use (Oncology, Musculoskeletal disorders, Wounds and injuries, Cardiovascular, System diseases, Surgery, Inflammatory and autoimmune diseases, Nervous system disorders, Drug Discovery, Others); End Users (Hospitals, Ambulatory Surgical Centers, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 Medical Tubing Market: By Type (Non-sterile Tubing, Sterile Tubing); Material Type (Polyethylene (PE), Silicone, Engineering Plastics, Polyvinyl Chloride (PVC), Polypropylene (PP), Polyolefin, Others); Medical Condition (Gastrointestinal, Cardiovascular , Ophthalmic, Urological, Neurovascular, Others); Application (Catheters, Drug Delivery Systems, Disposable Tubing, Dialysis Tubing, Surgical Tubing, Diagnostic Tubing, Respiratory Tubing, Others); End User (Hospitals & Clinics, Home Healthcare, Ambulatory Surgical Centers (ASCs), Diagnostic Laboratories, Others); Sales Channel (Direct Sales, Distributors, Online Sales); Region—Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025–2033 About Astute Analytica Astute Analytica is a globally recognized market research and advisory firm, delivering data-driven insights and strategic intelligence to organizations worldwide. We offer comprehensive research solutions across a wide range of industries, including technology, healthcare, chemicals, semiconductors, FMCG, and more. Our reports provide in-depth analysis of market trends, competitive landscapes, emerging opportunities, and technological advancements, empowering businesses to make informed decisions in an evolving global environment. Supported by a team of seasoned analysts, economists, and industry experts, we are committed to delivering accurate, timely, and actionable insights. At Astute Analytica, client success is our priority. We offer customized research solutions that are both cost-effective and tailored to meet the unique needs of our clients. Contact:Mr. Vipin SinghAstute Analytica500 N Michigan Ave, Suite 600Chicago, Illinois, United StatesUSA: +1-888 429 6757Email: sales@ our Website: Website: Network Platform: Photo: View original content to download multimedia: SOURCE Astute Analytica Sign in to access your portfolio
Yahoo
07-02-2025
- Business
- Yahoo
CAR T-Cell Therapy Market to Reach US$ 22.2 Billion By 2032
CAR T-Cell therapy market growth is propelled by revolutionary results in treating certain blood cancers. New Delhi, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The global CAR T-cell therapy market valuation is poised to reach US$ 22.2 billion by 2032, with a CAGR of 30% during the forecast period from 2024 to 2032. The global CAR T-cell therapy market is experiencing extraordinary demand, propelled by revolutionary results in treating certain blood cancers. As of 2022, more than 487,294 people were diagnosed with leukemia around the world. The boom was caused by three things: growing cancer rates, CAR-T's clinical success (it cures 80% of some leukemias), and the hundreds of CAR-T clinical trials being conducted around the world. CAR-T therapies have had the most success so far in targeting B-cell CD19 antigens (which is why Kymriah and Yescarta exist). However, researchers are hunting down a range of other antigens in a broad variety of cancers. In addition, they are also looking at how to treat solid tumors with CAR-T cells. There are still many hurdles to overcome. The cost — more than US$ 450,000 per treatment — limits accessibility, as does the complicatedness of their manufacture. Severe side effects like cytokine release syndrome (CRS) and neurotoxicity are also serving as a solid barrier to market growth. Download Free Sample Copy @ Increasing Adoption of Combinational Approaches The demand for CAR T-cell therapy market is propelled primarily by the growing adoption of combinational approaches. The CAR-T therapy strategy has many hurdles to leap over like tumor resistance, limited cell function, and solid tumors being complicated. Combining other treatments with CAR-T helps to tackle cancer from multiple angles, improve the engineered immune cell's effectiveness, and manage side effects. Here are some examples of promising combination therapies in the CAR T-cell therapy market. Today, oncologist are combining CAR-T cells with different checkpoint inhibitors (pembrolizumab or nivolumab) to fully unlock their anti-cancer activity. BiTEs as a bridge between the CAR-T cells and other immune cells increase the chances of killing a tumor. Cytokines like interleukin-2 (IL-2) boosts persistence in a CAR-T cell. Oncolytic viruses strategically infecting and destroying cancer cells attract other healthy cells towards it and prime the immune response. Lastly, targeted therapies disrupt certain cancer pathways to work synergistically with a CAR-T. With more than 65% of ongoing clinical trials involving some kind of combination approach in place, these therapies have massive potential to deliver effective outcomes. For instance, studies show positive outcomes when integrating CAR-T with checkpoint inhibitors for lymphomas and solid tumors and there are synergistic effects when incorporating them for cytokine therapy. BiTEs might be the key to unlocking solid tumor outcomes. Preclinical studies suggest oncolytic viruses can also enhance CAR-T cell function. Lymphoma Leads CAR T-Cell Therapy Market, Driven by Success in B-Cell Lymphomas By indication, the CAR T-cell therapy market is segmented into leukemia, lymphoma, and myeloma. Wherein, hematological cancers account for 9% of all new cancer cases in the US. Lymphoma is projected to be a major market segment, occupying more than 40% of the market share. The initial success of CAR-T therapies that targeted the CD19 antigen (which is highly expressed in many B-cell lymphomas) was a huge reason they are now being utilized to treat this type of cancer. These therapies were utilized for relapsed and refractory B-cell lymphomas and had amazing results, which led to them becoming so widely adopted. Lymphomas also have a more favorable environment for CAR-T therapies than solid tumors usually do. Blood cancers are much easier for these cells to access, and their tumor microenvironment tends to be less immunosuppressive too. On top of all that, patients who relapse after chemotherapy or stem cell transplants usually don't respond well to those treatments the second time around. That is why there is such a high demand for the global CAR T-cell therapy market in this field; it is an alternative that works when other choices fail. This has caused clinical trials investigating CAR-T for different lymphoma subtypes to multiply rapidly as well. Kymriah, Tecartus, Yescarta, and Breyanzi are four types of CAR-T therapy that have already been approved by the FDA for specific B-cell lymphomas too — just another thing boosting their popularity and use. Monotherapy Dominates CAR T-Cell Therapy Market, While Combination Therapies Gain Momentum Based on the type of therapy, the CAR T-cell therapy market is further segmented into monotherapy and combination therapy. More than 80% of CARTs are autologous, with most being utilized as monotherapy. As a standalone treatment, CAR-T therapy was initially very successful. The promising results targeting CD19 in B-cell cancers prompted its development and regulatory approvals. Most of the currently FDA-approved CAR-T therapies - including Yescarta, Kymriah, and Breyanzi - were designed to be utilized as monotherapy. This reaffirms the usage of CAR-T as a lone treatment alternative. Furthermore, while investigation into combination therapies is quickening up, managing the potential complications of combining CAR-T with other treatments like checkpoint inhibitors remains at an early stage. Particularly since the focus on CAR-T for solid tumors — where combinations may be more significant — is still less developed than for blood cancers across the global market. For instance, patients with relapsed or refractory B-cell lymphomas usually show a significant response to commercial CAR-T monotherapies like Kymriah and Yescarta. In multiple myeloma, BCMA-targeted CAR-T therapies such as Abecma are also predominantly utilized as monotherapy after other lines of treatment have already been exhausted. Key Players Novartis AG Bluebird Bio, Inc. Cellectis Bristol-Myers Squibb Merck & Co., Inc. Juno Therapeutics, Inc. Celyad Oncology Celgene Corporation Sorrento Therapeutics, Inc. Miltenyi Biotech Intellia Therapeutics Pfizer, Inc. Autolus Therapeutics Gilead Sciences, Inc. (Kite Pharma Inc.) Cartesian Therapeutics, Inc. Caribou Biosciences, Inc. Other Prominent Players Key Segmentation: By Indication Leukemia Lymphoma Myeloma By Source Autologous Allogenic By Type of Therapy Monotherapy Combination therapy By Product ABECMA Breyanzi Carvykti Kymriah Tecartus Yescarta By Administration Setting Inpatient Outpatient By Region North America Europe Asia Pacific Middle East & Africa (MEA) South America For more information about this report visit: About Astute Analytica Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
